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Abstract
Background: Decision Aids (DAs) effectively translate medical evidence for patients 
but are not routinely used in clinical practice. Little is known about how DAs are used 
during patient- clinician encounters.
Objective: To characterize the content and communicative function of high- quality 
DAs during diagnostic clinic visits for prostate cancer.
Participants: 252 men newly diagnosed with localized prostate cancer who had re-
ceived a DA, 45 treating physicians at 4 US Veterans Administration urology clinics.
Methods: Qualitative analysis of transcribed audio recordings was used to inductively 
develop categories capturing content and function of all direct references to DAs 
(booklet talk). The presence or absence of any booklet talk per transcript was also 
calculated.
Results: Booklet talk occurred in 55% of transcripts. Content focused on surgical pro-
cedures (36%); treatment choice (22%); and clarifying risk classification (17%). The 
most common function of booklet talk was patient corroboration of physicians’ expla-
nations (42%), followed by either physician or patient acknowledgement that the pa-
tient had the booklet. Codes reflected the absence of DA use for shared decision- making. 
In regression analysis, predictors of booklet talk were fewer years of patient education 
(P = .027) and more time in the encounter (P = .027). Patient race, DA type, time read-
ing the DA, physician informing quality and physician age did not predict booklet talk.
Conclusions: Results show that good decision aids, systematically provided to pa-
tients, appeared to function not to open up deliberations about how to balance ben-
efits and harms of competing treatments, but rather to allow patients to ask narrow 
technical questions about recommended treatments.
K E Y W O R D S
decision aids, patient-centred communication, prostate cancer, qualitative research, shared 
decision-making, veterans
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1  | INTRODUCTION
Patient decision aids (DAs) describing treatment options and risk/ben-
efit trade- offs among treatments have been successfully developed 
and tested over several decades, beginning, for early- stage prostate 
cancer, in 1988.1,2. While DAs are effective information translation 
tools, they are not routinely used in clinical practice.3 Systematic re-
views of DA tools show they increase patient knowledge, increase pa-
tient clarity about their own values, decrease decisional conflict and 
increase patient interest in active roles in decision- making. However, 
despite growing support for shared decision- making in practice guide-
lines and continued development of new DAs, little is known about 
how patients and clinicians actually use DAs during clinical encounters.
DAs have been increasingly incorporated into communication and 
decision- making interventions.4 DAs are usually developed for those 
conditions that are preference sensitive, meaning conditions with 
competing treatment or screening options that offer similar survival, 
with different side- effect profiles. Initial treatment for clinically local-
ized prostate cancer provides the classic example of a preference sen-
sitive decision, as mortality is almost equivalent among surveillance 
(either active surveillance or watchful waiting), radiation therapy and 
prostatectomy.5,6 Side effects of prostatectomy and radiation can in-
clude erectile dysfunction and bladder and bowel dysfunction, while 
surveillance requires follow- up testing and may cause anxiety about 
living with cancer.7-10
DAs have been implemented both in preparation for the clinical 
encounter (with and without patient coaching) and within the clinical 
encounter. The most recent update of the Cochrane Review of DAs 
found that of 105 studies, implementation in preparation for the clin-
ical encounter occurred in 85% of included studies.1 Both implemen-
tation strategies improved knowledge and more accurate patient risk 
perceptions.
While previous studies have shown that DAs have potential to 
positively impact both patient informing and patient- clinician interac-
tion, little is known about the role that DAs play during the exchanges 
between patients and clinicians. The impact of DAs on the clinical en-
counter is assumed more often than examined. Of the 105 studies 
included in the most recent Cochrane review,1 10 studied the effect 
on communication. Of those, the five studies that implemented the 
DA in preparation for the consultation all used self- report measures of 
decision- making.11-15 To our knowledge, no previous study has used 
data from direct observation of patient- clinician communication (ie, 
data from transcripts or recordings of clinic visits) to identify how pa-
tients and clinicians actually use and discuss DAs during encounters. 
Analysis of transcripts or recordings (rather than reports based on pa-
tient or clinician recollection) is not subject to hindsight bias16 and is 
generally considered the most accurate method for assessing the con-
tent of communication during clinic visits.17,18
In this study, we analysed visit transcripts to investigate the 
content and communicative function of direct references to DAs in 
patients’ post- biopsy urology clinic encounters during which ini-
tial treatment decisions for clinically localized prostate cancer were 
made. We analysed transcripts for these visits to inductively develop 
categories capturing content and function of direct references to DAs 
(“booklet talk”). We also examined patient and clinician characteristics 
associated with the presence of a reference to a DA during the en-
counter. Understanding what content is discussed in direct reference 
to a DA, and how the DA functions in the encounter fills a knowledge 
gap about patient- clinician communication following standardized DA 
provision. Understanding how DAs are discussed during encounters 
can help researchers and clinicians to design more effective DAs and 
implementation strategies.
2  | METHODS
Audio recordings and survey data were obtained from a multisite clini-
cal trial that compared two prostate cancer DAs, to determine their 
relative impact on treatment choice. Patients undergoing prostate biop-
sies were recruited from four US Veterans Administration (VA) Health 
Systems (Ann Arbor, Durham, Pittsburgh and San Francisco) between 
September 2008 and May 2012. At recruitment, when the biopsy 
was performed, each patient was randomized to receive either a plain 
language DA (designed by the Michigan Cancer Consortium (MCC)19, 
or a standard language DA (designed by the National Comprehensive 
Cancer Network (NCCN) and American Cancer Society (ACS). The 
MCC DA was developed to use plain language and to adhere to the 
standards of the International Patient Decision Aids Consortium 
(IPDAS).20 The current version of the MCC DA can be found at www.
prostatecancerdecision.org. The NCCN DA was chosen because of 
its high- quality information and the high credibility of the sponsoring 
organizations. The current version of the NCCN DA can be found at 
https://www.nccn.org/patients/guidelines/prostate. Both decision 
aids used the terminology “watchful waiting” because the term, “active 
surveillance” was not a commonly used term when this study was con-
ducted. Therefore, we use watchful waiting throughout. (More detailed 
quality analysis of the DAs can be found in the Appendix S1).
Block randomization was used to ensure that equal numbers of 
African American and low- literacy patients received each decision 
aid. Physicians were aware that patients received a DA, but not given 
any further instructions in DA use. In addition to transcripts of audio 
recordings, survey data describing patient characteristics and self- 
reported DA use were available for analysis from the parent trial.
Patients with clinically localized prostate cancer (Gleason score 6 
or 7, PSA < 20 ng/mL) were asked to participate in audio recording of 
the first post- biopsy encounter, the one at which the patient first re-
ceived his diagnosis and discussed initial treatment options. Surveys 
were administered at three time points: biopsy, immediately before the 
physician encounter and 7- 10 days following the physician encounter. 
Patients were called 2 days before the physician encounter and re-
minded to read the DA, but were not informed of their diagnosis. They 
learned their diagnosis from the physician, with the exception of one 
site that followed a practice of giving the diagnosis over the telephone. 
Participants at that site were interviewed before the diagnosis phone 
call. Physician participants were urology residents and attending phy-
sicians. All provided demographic data at the time of recruitment. The 
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study was approved by the VA Institutional Review Boards at each 
participating site; written informed consent was obtained from each 
patient and physician participant. The funding agencies had no role in 
conduct or reporting of the parent study or the analysis presented in 
this manuscript.
2.1 | Measures from the parent study
We obtained descriptive data from the parent study. Survey measures 
completed by patients before the clinical encounter included patient 
literacy21 and numeracy22, preference for shared decision- making23, 
prostate cancer treatment knowledge related to survival benefit and 
side- effects associated with treatments,24-26 treatment preference, 
use of and satisfaction with DA and demographics (patients’ race, eth-
nicity, age, marital status and education).
A measure of the quality of physician informing was obtained 
through a transcript analysis. The Informed Decision Making (IDM) 
score,27 is a standardized observational measure of the quality of phy-
sician informing behaviour, scored by analysing transcripts of audio- 
recorded patient encounters.28 Patients’ PSA level, Gleason Score and 
treatment received were obtained from electronic medical records.
2.2 | Audio recordings and transcripts for this  
analysis
A research associate sets up an audio recorder in the examination 
room at the start of each visit and then waited outside the exami-
nation room until the visit was complete. Recordings were later an-
onymized and transcribed verbatim. Of 256 transcripts, 252 were 
available for inclusion. Two transcripts were excluded because of re-
corder malfunction; two encounters were only to obtain a referral to 
radiation oncology. Time in the encounter was measured directly from 
the audio recordings. Time when the physician was out of the room 
was subtracted from total time to yield the net time the physician was 
in the room with the patient.
2.3 | Coding and qualitative analysis
In this analysis, we coded and analysed direct references to the DA 
and used a two- step coding process to identify the content catego-
ries and function categories to describe how the DA functioned in the 
exchange. In step one, two coders independently identified all direct 
DA references. In addition, a word search of the text was performed 
using the words “booklet”, “pamphlet”, “book” and “decision aid” to 
check for missing episodes. Booklet talk was classified into one of four 
transactional categories: (i) patient initiates and doctor responds, (ii) 
patient initiates and doctor fails to respond, (iii) doctor initiates and 
patient responds and (iv) doctor initiates and patient fails to respond. 
Coding exchanges (ie, topic initiation and response) accounts for the 
interactional nature of clinic visits and is a common approach when 
coding patient- clinician communication.29,30
Because we previously noted that communication tasks during 
these visits occurred in a predictable sequence,31 we analysed a 
random sample of 28 transcripts to evaluate whether booklet talk also 
occurred in predictable portions of visits, for example. after diagnosis 
delivery, during treatment choice discussions, at the close of the en-
counter. To do this, we calculated the percentage of total words in each 
transcript before each episode of booklet talk and analysed the distri-
bution of results in the 28 randomly sampled transcripts. The wide 
distribution of percentages of words before episodes of booklet talk 
(range = 1- 99) and no clear clustering pattern, suggested there was no 
part of the clinical routine that triggered booklet talk. We therefore did 
not pursue a separate structural analysis of the encounters.
In step two, we inductively developed the set of content and 
function codes for each coded exchange by carefully analysing a ran-
dom pilot set of fourteen transcripts. No constraints were placed on 
identification of content. Seven investigators independently applied 
the initial coding system to a second set of fourteen transcripts, re-
solved disagreements and modified the coding system until the codes 
could be applied reliably. Resulting content codes were: (i) treatment 
options, (ii) side- effects, (iii) treatment choice/decision, (iv) risk classi-
fication, (v) nature of cancer and (vi) booklet quality.
Function codes captured the conversational work being done by 
booklet talk during the exchanges. Resulting function codes identified 
that the speaker: (i) acknowledges the booklet, (ii) gives advice or in-
formation, (iii) confirms or validates what was said, (iv) flags record- 
keeping opportunity, (v) requests information, (vi) uses booklet to 
question doctor and (vii) expresses concern or fear. Complete defini-
tions can be found in Tables 1 and 2. Each instance of booklet talk had 
at least one content and one function code. Codes were not mutually 
exclusive, (eg, an exchange could have more than one content and/
or function code). We found no booklet talk exchanges that could be 
considered shared decision- making. A final set of coding rules with ex-
amples was developed. Complete coding rules are available from the 
corresponding author.
Six coders working in 3 pairs applied the final coding system to all 
252 transcripts. Two coders independently coded each transcript; dis-
crepancies were resolved by consensus. Coders were blinded to plain 
language vs standard language DA allocation. For rates of the presence 
or absence of booklet talk, the unit of analysis was the transcript. For 
frequency of occurrence of content and function codes and for fre-
quency of speaker exchanges, the unit of analysis was the total num-
ber of coded exchanges. To describe the distribution of content codes 
across all transcripts, we compiled all instances of each content code 
that appeared in the codebook. The denominator for this analysis (298 
codes) exceeds the number of episodes across all transcripts because 
an episode could include more than one topic. Coding was completed 
in Dedoose.32 Dedoose is, a Rich Internet Application (RIA) that allows 
data analysis and handling from mixed methods research. Frequencies 
and descriptive statistics were calculated using Microsoft Excel.33
2.4 | Regression analysis
To identify predictors of booklet talk during the consultation, we con-
ducted two mixed effects logistic regression models, using patient, phy-
sician and encounter level variables from the parent study to predict the 
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presence of booklet talk in the transcript. Among the variables available 
in the parent study, we prioritized those with a theoretical relationship 
to the likelihood of mentioning the DA in the encounter. Patient educa-
tion and race have been previously associated with how much patients 
participate in encounters with physicians.34-37 Time spent reading the 
DA before the encounter was included as a measure of interest in the 
content. Age was not included because of the narrow range of patient 
ages. Time in the encounter, measured in minutes from the recordings, 
was included because trials of DAs have been shown across studies 
to sometimes shorten and sometimes lengthen encounter times.38,39 
DA type (plain vs standard language) was also included as a variable, as 
randomization in the original study was based on DA type.
The binary booklet talk variable (yes/no) was used as the main 
outcome in the logistic regression models. Specifically, to account for 
patient, visit and physician variables in the models, two mixed effect 
logistic regression models were conducted in Stata data analysis and 
statistical software version 14.040 (using the melogit command). The 
first model only included patient and visit level variables (ie, education, 
race, DA type, time spent reading the DA and time in the encounter), 
with physician ID number treated as a random intercept to account 
for potential variation by physician. The second model added physi-
cian level variables, including physician age and the IDM score. For 
completeness, we only evaluated cases that had complete data for 
each variable in the models, making the final n in the mixed effects 
model 236/252 transcripts.
3  | RESULTS
Demographic characteristics for the 252 patients are shown in Table 3. 
The mean age of the patient sample was 63.3 years (SD = 5.9); 33% 
were non- white; 40% had high school education or less. The mean age 
of 45 treating physicians was 33 (SD = 7.2); 20% were women, 34% 
were non- white. On average, each physician was recorded in 6 clinical 
encounters (SD = 4.3) and was 10 years post- graduation.
References to a DA, (“booklet talk”), occurred in 138/252 tran-
scripts (55%). In the 138 transcripts containing booklet talk, there 
were 214 separate booklet talk episodes, with a maximum of 5 in a 
single transcript, a mean of 1.55 (SD .81) and a mode of one. Of the 
214 booklet talk episodes, 120 (56%) were patient initiated. The ob-
served rate of booklet talk per transcript was consistent with the rates 
reported in the surveys. In the post- encounter surveys, 55% of pa-
tients reported bringing the DA to the encounter, while 90% reported 
reading the DA before the encounter (data available on request).
Function code Function code definition Frequency (%)
Learn more or confirm/
validate
Doctor or patient utilizes the booklet to learn 
more or validate something read in the booklet
41
Acknowledges booklet Doctor or patient acknowledges the patient has 
the booklet
28
Request for information 
or question
Patient utilizes the booklet to ask a question 12
Advice or information 
giving
Doctor utilizes the booklet to give advice or 
provide the patient with more information
6
Record- keeping Doctor or patient suggests writing notes in the 
booklet
5
Uses booklet to question 
doctor
Patient uses the booklet to challenge the 
physician
4
Expression of concern Doctor or patient expresses concern specifically 
from something seen in the booklet
4
TABLE  2 Booklet talk function codes
Content code Content code definition Frequency (%)
Treatment options Booklet is referenced when discussing different 
treatment options.
36
Treatment choice/
decision
Booklet is referenced when discussing making the 
actual treatment decision
22
Risk classification Booklet is referenced when discussing PSA, grade 
and stage.
18
Side- effects Booklet is referenced with respect to side- effects 
of treatment options
8
Nature of cancer Booklet is referenced with respect to the generally 
slow growth of early- stage prostate CAs
8
Booklet quality Any positive or negative statements regarding the 
quality or utility of the booklet
8
TABLE  1 Booklet talk content codes
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3.1 | Content and function
DAs were referenced most frequently during discussion of treatment 
options (36%). The most common specific content code was details of 
surgery. Direct references to making a treatment decision constituted 
22% of all content codes; clarification of technical information about 
risk classification, 18%. Frequencies for all content codes are shown in 
Table 1, and examples of each content code appear in Table 4.
Function codes describe how the DA references were used in 
the encounter. As in the content codes, we compiled all instances of 
each function code that appeared in the codebook. The denomina-
tor for this analysis (316 codes), like content, exceeds the number of 
episodes. All exchanges were coded for both content and function. 
The functions were dominated by “learn more or validate” (41%) and 
“acknowledging the booklet” (28%). “Learn more” was usually a pa-
tient request to hear the physician’s explanation for or interpretation 
of something the patient read in the DA. “Acknowledging the booklet” 
was usually a physician question about whether the patient received 
a DA or a comment that s/he saw the patient carrying a copy of the 
DA. The third most frequent category was consistent with the design 
of DAs, “using the booklet to ask a question” (12%). Examples of each 
category of function codes appear in Table 5.
Occasionally, patients referred to the booklet to explain how wor-
ried they were about their prostate cancer or specific treatments. The 
DA, in these instances, appeared to serve as either reassurance, or as 
a vehicle for expressing concern to the physician. (See Table 5.) Patient 
references to the DA to challenge the physician’s recommendation 
were rare.
3.2 | Predictors of booklet talk
Results of the first mixed effects regression model revealed that only 
education and time in the clinical encounter predicted reference to 
TABLE  3 Participant characteristics
Sample (n = 252)
Age M = 63, SD = 6.01
Race (%)
Caucasian 185 (73)
African American 67 (27)
Other 0 (0)
Education (%)
<High school 5 (2)
High school grade/trade 79 (31)
Some college/Assoc. 116 (46)
BA+ 52 (21)
Marital status (%)
Married/partner 131 (52)
Divorced/separated 94 (37)
Widowed 7 (3)
Single 20 (8)
TABLE  4 Examples of booklet talk content codes
Treatment options
Example 1
PAT- Yeah, so removing the prostate effects what other body 
functions or anything?
DOC- That’s basically it, urinary and erectile functions
PAT- Ok
DOC- No other real body functions
PAT- Body doesn’t need that
DOC- It needs it if you want kids, it needs it if you um. Yeah your 
body doesn’t really need it
PAT- After reading that book, the radiation seems the better…… but 
that’s not what you’re saying, it’s not really.
DOC- There’s benefits and risks to both
Example 2
PAT- In the book there was two types of radiation
DOC- Right there’s the seeds that they can put into your prostate or 
radiation from the outside, where they focus all the energy
PAT- Some beam or something
DOC- Yeah external beam radiation
Treatment choice/decision
Example 1
PAT- I’ll just come back in like two to four weeks.
DOC- Okay, alright. Um, I think that’s a very, very reasonable, um 
again, this is a low risk prostate cancer. You’ve got good treatment 
options available, and um, you’ll have the reading material that you 
got from to kind of help you navigate these decisions. Um, if you 
have any other questions or concerns, don’t hesitate to call back 
over here to the clinic, you can talk to whichever one of the doctors 
is down here.
PAT- Okay.
DOC- Okay, and um, you know, we’re happy to kind of help you make 
whatever decision it is that you want to make, whether that’s 
surgery or radiation.
Example 2
DOC- Okay um, and even with aggressive disease….. the chance it can 
affect your lifespan at five years is low. It interests me that some 
patients say, “Listen I really want this tumor out.” And we get the 
tumor out, it’s cancer, even despite the fact that I tell them that not 
all cancer is the same.
PAT- Sure
DOC- Okay
PAT- Well, like she had breast cancer and she immediately wanted it 
out. I basically said the same thing the other day. If I find out I have 
cancer I immediately want it out. But now, that I you know, read 
some of that and after talking with you I got a little, “Yeah it’s, we’ll 
do the wait and see approach for awhile.”
DOC- The only caveat about the wait and see approach again is that, 
you’re a little different than the typical wait and see approach patient.
Risk classification
PAT- I’m, I’m confused about the three plus three, I have to interrupt 
you I’m sorry.
DOC- That’s no problem you can feel free to interrupt as, ask me
(Continues)
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the booklet (ie, booklet talk). Specifically, higher education was associ-
ated with lower odds of the booklet’s being discussed in the clinical 
encounter. Odds of booklet talk among patients with some college 
or trade school education had an OR = 0.45 (95% CI = 0.22- 0.90, 
P = .024) compared with those with a high school degree or less. Odds 
of booklet talk of those with a 4- year college degree and beyond had 
an OR = 0.42 (95% CI = 0.18- 0.96, P = .041) compared with those 
with a high school degree or less. Longer time spent in the clinical en-
counter predicted higher odds of the DA being discussed (OR = 1.03, 
95% CI = 1.00- 1.06, P = .034). We have previously shown that time 
in the encounter varied widely and was modestly associated (r = .24, 
P = .01) with the IDM score. In this analysis, time in the encounter, but 
not IDM score predicted booklet talk. Patient race, DA type and time 
spent reading the DA were not significant predictors of booklet talk.
In the second model, we tested whether adding physician level 
variables capturing physician experience and their quality of inform-
ing patients about treatment decision- making would cause patient 
education and time in the encounter to drop out as significant pre-
dictors. Patient’s level of education remained significant, but only for 
those with some college or trade school education (OR = 0.46, 95% 
CI = 0.23- 0.91, P = .027). In both models, men with only a high school 
education referred to the booklet more often than more highly edu-
cated men. Time in the clinical encounter also remained significant. 
In longer clinical encounters, the booklet had higher odds of being 
discussed (OR = 1.03, 95% CI = 1.00- 1.07, P = .034). Patient race, DA 
type, time spent reading the DA, the IDM score and physician age 
were not significant predictors of booklet talk.
4  | DISCUSSION
While many DAs have been shown to be effective in translating medi-
cal evidence for patients, they are not routinely used in practice.1,3 
Our results contribute to better understanding of this implementation 
conundrum. We found that DAs appeared to function not to open up 
deliberations about how to balance benefits and harms of competing 
treatments, but to allow patients to ask narrow technical questions 
about recommended treatments. This was contrary to expectations, 
as we chose high- quality DAs, shown previously to be engaging to 
patients.19 We found no evidence that DAs functioned to facilitate 
shared decision- making in the encounter.
Direct references to DAs occurred in over half of encounters. 
Direct references to the DA were more frequently initiated by patients 
than physicians. This may in part, be attributable to the fact that physi-
cians did not receive any training in DA use, while patients were asked 
to use the DAs to prepare for the encounter. However, the analysis 
PAT- This book is talking about a PSA number and then they’re talking 
about a Gleason s….
DOC- Correct
PAT- What is the PSA number
DOC- His PSA is four point two
PAT- Four point two?
DOC- Correct
PAT- The, the, the Gleason number you’re giving me you keep saying 
three plus three?
DOC- Or six
PAT- So his Gleason number is six?
DOC- Correct
PAT- In this book it’s saying a Gleason number of six is not the 
slowest growing, it’s the medium
DOC- No, it’s the slowest growing.
Side effects
Example 1
DOC- Okay, what would you like to hear more about? I mean I guess I 
can talk most about the prostatectomy; do you have a thought?
PAT- Well, you know they have these questions and I might ask them 
in you know, how does the regular side effects in this booklet 
compare to the regular side effects in your practice.
DOC: Oh, and I’m not sure what’s in the booklet, I should probably 
read this a little more closely.
Example 2
PAT- And what’s that to do with, going the bathroom?
DOC- That is how you keep your urine in and not let it leak out
PAT- I thought I’d read some of that in there. I says, “I’d hate to have 
to run into a problem like that.”
DOC- Yeah. And that is a possibility, it is a slight possibility with 
radiation as well but not as much. But those are your biggest 
problems that we have, that we see with patients after surgery.
Nature of cancer
DOC- Yeah, and now we know so um we’ll have you come back in a 
couple months
PAT- Ok
DOC- Alright
PAT- This type of cancer from what I read in the book is extremely 
slow growing
DOC- Yes, but you seem healthy enough that you will probably live 
another 20- 30 y at least
PAT- That’s what I figured, you know I’m not that old yet
Booklet quality
DOC- Do you have access to the web?
PAT- Yep
DOC- It does a pretty good job of um, um it does a pretty good job 
about um, explaining treatment options and everything.
PAT- Okay, better than this book that I got?
DOC- Yeah
PAT- Really?
TABLE  4  (Continued)
(Continues)
DOC- Yeah
PAT- That was pretty straight forward and simple and
DOC- The problem with those books is sometimes they are little bit 
out of date.
TABLE  4  (Continued)
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TABLE  5 Examples of booklet talk function codes
Acknowledges booklet
Example 1
DOC- It gives you time to digest, you seem like the type of guy that 
you in good health will live a while longer so I do recommend some 
type of treatment but what you choose is up to you. Both are equally 
good
PAT- Is there literature
DOC- Yeah, they give you anything?
PAT- Yeah…..gave me one book
Example 2
DOC- And have you done some reading about it?
PAT- Yeah she gave me that book and that’s the only thing and I’m 
not afraid of the procedure, it’s just the
DOC- The possibility of being incontinent afterwards
PAT- Yeah
Advice or information giving
Example 1
DOC- You just have to remember like when you’re coming to see 
urology. Okay, so, well I think if you all don’t have any other 
questions, of course if you do have questions between now and then
PAT- Um- hmm
DOC- Just feel free to call us, or if you change your mind, you read 
something in there and you say you know what I do want to talk to 
the radiation doctors just give us a call, we can set that up.
Example 2
DOC- Okay? So let’s do this let’s return to clinic in 3 wk. Alright does 
that sound like a good plan?
PAT- Yeah
DOC- And if you have any questions like I said, the handout is pretty 
good it’s pretty detailed but it definitely will a
PAT- Yeah
DOC- You know help you maybe think through things and then 
talking to the oncologist or to the radiation doctors would be great
Learn more or confirm/validate
Example 1
DOC- um, for people that have high risk cancer and sometimes people 
have intermediate cancer we do get them the CAT scan and the 
bone scan to make sure it’s nowhere else, but that’s typically for 
higher risk, higher risk disease.
PAT- Yeah I was thinking, I read about that, that bone scan, CT scan 
and whatever other scans they’ve got. You wouldn’t do that? I mean 
that’s not, that’s not an option to do?
DOC- Oh, it’s, it’s, it’s typically you know, it’s, it’s not usually that it’s 
not an option, it’s always an option. It’s just that for people with like 
low and intermediate risk prostate cancer, it’s usually not necessary 
because the odds that it’s spread are so low.
Example 2
PAT- Right, and can you put some information in my booklet?
DOC- I sure can, I can do that. Why don’t I do this when we get 
finished with this because yeah, I’ll put some information in here. 
What are your thoughts about what you’ve read here?
(Continues)
PAT- Well uh, I kind of thought that if it was low grade or anything, 
that uh, you know, we’d probably keep pretty close watch of it and 
uh, monitor it closely and so on and if it reaches a stage where, 
where, you know, where we determine that it needs pretty much, 
you know, prompt attention and so on and so forth, why we’ll go 
ahead and give it to it, you know, you know, just go ahead and give 
it, do what’s necessary then in that case. I was leaning a little bit 
towards treatment options of uh, now as far as percentage of cure 
and so on, radiation as compared to surgery, what are the basic 
percentages?
Record-keeping
PAT- Okay so that’s what they call, can we mark this down?
PAT 2- Did you say its three?
DOC- Plus three, Gleason six,
PAT- There’s places on that book they gave is very helpful so
DOC- Sure, sure
PAT- I want to be able to fill that out, uh, as we’re going around. 
We’re going to have some questions for you.
Request for information or question
PAT- Now, again I’m going to ask the questions Doc, what grade is it?
DOC- Low grade
PAT- Low grade, and it’s, the cells are they in the stage….. alright, 
here’s what, and I don’t know I’m not a doctor, my son is but I’m not. 
In this booklet that they got here, here we go. I’m a stage one or two 
right?
DOC- Stage one.
Uses booklet to question doctor
DOC 1- That’s low grade, it goes from the Gleason.
PAT- If the high is ten, you’re over half.
DOC 2- Right, but the lowest grade that they call is six
DOC 1- Right
DOC 2- It’s a scale of six to ten, not, not zero to ten
PAT- Not according to this book
DOC 2- Yeah. Well the pathologists don’t call Gleason fives anymore, 
they used to, but they don’t anymore.
Expression of concern
Example 1
PAT- Whenever I start getting upset or nervous about this I can take 
this out and start reading through it again. The way things are 
explained in here kind of calms you down.
DOC- Well yeah, that’s good to know.
Example 2
DOC- Do you have access to the web?
DOC- Is that the material that they give you?
PAT 2- It’s the book, yeah. We both read it so
DOC- I see
PAT 1- Gives you something
DOC- It’s good, no, it’s an excellent resource. You know,
PAT 1- Well, it makes you sweat.
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of function codes revealed that patients largely used the DA to cor-
roborate what the physician said or to request more technical detail. 
Specifically, 41% of booklet talk functioned to validate or prompt ad-
ditional discussion of a topic (“learn more”); the most common topic 
discussed when referencing the DA was details of specific treatment 
options. Patients only used the DA as a platform for asking the physi-
cian a question in 12% of transcripts (see Table 2). Patient questions 
were often about prognosis and treatment options. While it may be 
that patients with specific questions brought the DA along, it sug-
gests that encouragement to patients to bring a DA to the encounter 
may increase the likelihood that the DA content is discussed in the 
encounter.
Patients did not use the DA to articulate their outcome prefer-
ences and goals as encouraged in the DAs themselves. Nor did they 
use the DA to bring up treatment outcomes or use the DA to say what 
side- effects concerned them. Rather, booklet talk fit into a physician- 
driven medical routine focused on understanding biopsy results and 
reviewing treatment options to settle on a treatment. This use of the 
DA is consistent with a companion analysis of this data set showing 
that physician recommendations dominated treatment preference.41 
That analysis showed that for these low and intermediate risk prostate 
cancer patients, treatment decisions were based largely upon urolo-
gists’ recommendations, and not on patients’ personal views of the 
relative pros and cons of treatment alternatives. Urologists’ recom-
mendations, in turn, were influenced heavily by medical factors (age 
and Gleason score) but were unrelated to patient preferences. While 
the presence of a DA did not appear to influence the informing and 
treatment choice process, it did appear to support patient understand-
ing of treatment choices. In addition, both DA booklets stimulated 
booklet talk, suggesting that actual use of the DA in the encounter is a 
generalizable phenomenon across different DAs.
Regression analysis showed that less well- educated patients were 
more likely to mention the DA. This finding is not unexpected. In our 
prior research, we found that patients with less education gained more 
knowledge from a DA.42 It is one of the unique characteristics of DAs 
that those who are less knowledgeable before reading a DA gain the 
most knowledge. DAs are also designed to provide an authoritative 
source to help patients ask questions.1 Time in the encounter, but not 
the quality of physician informing (IDM score) predicted booklet talk. 
This lends support to earlier findings that discussing patient questions 
raised by a DA may take a small amount of extra time in the encounter. 
The Cochrane Review of DAs shows that the association of DA use 
with time in the encounter is highly variable, sometimes associated 
with	shorter	and	sometimes	with	longer	encounters	(range	−4	minutes	
to +23 minutes), with an average of 2.6 minutes longer1. It is import-
ant to note that in this study, which over- sampled African American 
patients, race was not a predictor of booklet talk. This suggests that 
minority and white patients were equally likely to use the DA in the 
encounter.
While there are studies of patient- clinician communication 
 focused on measuring the presence of shared decision- making,43 
we know of none that investigates how DAs function in real time 
during the consultation. We extend previous research on DA use by 
describing what issues from the DA were brought up, and how they 
functioned in doctor- patient communication about treatment de-
cisions for localized prostate cancer treatment. This augments prior 
research about DA effects based on self- report measures of patient- 
clinician communication. In these geographically distributed Veterans 
Administration clinics, DAs were used as an adjunct to physician treat-
ment recommendations. A limitation of this study is that only explicit 
mentions of DAs were coded. Other patient questions may have been 
stimulated by DAs that were not explicitly linked to the DA as booklet 
talk. However, as the field moves towards DA use to support decision- 
making that reflects patient values, it will be critical to understand 
what actually happens during DA implementation in clinical encoun-
ters across settings.
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